CION Ameerpet
A breast cancer diagnosis is made through "triple assessment" — a clinical examination, imaging (a mammogram and/or breast ultrasound), and a biopsy that confirms the answer under the microscope. No diagnosis is final until a pathologist has examined biopsy tissue. This page walks you through every step, from finding a lump to receiving a staged, receptor-typed report — and at CION, the whole pathway is woman-led, tumour-board-reviewed and free for your first consultation.
Diagnosing breast cancer is a step-by-step process, not a single test. It usually begins when a woman notices a change — most often a lump — or when something is picked up on screening. From there, doctors use a structured approach called the triple assessment: a clinical breast examination, imaging, and a tissue biopsy. Only when all three are put together can a diagnosis be confirmed and the cancer fully characterised.
Crucially, imaging can suggest cancer but it cannot prove it. A confident diagnosis always rests on a biopsy, where a pathologist examines cells or tissue under a microscope. The biopsy report then tells your oncologist the cancer's type, its grade, and its receptor status — the information that decides which treatments will help you.
Clinical exam, imaging and biopsy combined — the internationally recommended way to evaluate any breast change, because no single test is enough on its own.
Cancer is only confirmed when tissue is examined under the microscope. A normal scan does not always rule out cancer, and a worrying scan still needs tissue confirmation.
The biopsy and staging reports reveal type, grade, ER/PR/HER2 status and spread — everything the tumour board needs to plan your treatment.
A breast cancer diagnosis is never made on a scan alone. Imaging — a mammogram, ultrasound or MRI — can raise or lower suspicion, but the diagnosis is only confirmed when a pathologist examines biopsy tissue under the microscope. That is why a worrying scan is followed by a biopsy, and why CION never starts cancer treatment without tissue confirmation. Source: NCCN Breast Cancer guidance; standard triple-assessment practice.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
The triple assessment is the foundation of breast diagnosis worldwide. Each of its three parts answers a different question, and their accuracy is far higher together than apart. If all three agree, the answer is very reliable; if they disagree, the team investigates further rather than guessing.
Understanding the three pillars helps you know what to expect at each visit and why you may be sent for more than one test even after a "normal" scan.
A doctor feels both breasts and the underarm and neck lymph nodes, noting the size, texture and position of any lump and any skin or nipple changes. This builds on what a woman finds during a breast self-examination.
A mammogram is usually first in women over 40; a breast ultrasound is added for younger women and dense breasts, and a breast MRI is used in selected cases.
If imaging is suspicious, a sample is taken — usually a core needle biopsy, sometimes an FNAC — so a pathologist can confirm whether cancer is present.
Each test has limits — a small cancer can be missed on a mammogram, and a benign-looking lump can occasionally be cancer. Combining exam, imaging and biopsy minimises both false reassurance and false alarms.
Imaging maps the breast and points the doctor to anything that needs a biopsy. Different scans suit different breasts and situations, which is why you may have more than one. None of them, on their own, can confirm cancer — they guide the biopsy that does.
A low-dose breast X-ray, the main tool for women over 40. It can find small cancers and tiny calcium flecks (microcalcifications) before a lump can be felt. Learn more on our mammogram page.
Uses sound waves and is especially useful in younger women, dense breasts and during pregnancy. It tells a solid lump from a fluid-filled cyst and guides needle biopsies — see our breast ultrasound page.
A detailed magnetic-resonance scan used in high-risk women, when other tests are unclear, and to map disease before surgery. Read about it on our breast MRI page.
A scan can look highly suspicious or completely reassuring, but it cannot tell you the cell type, grade or receptor status. Those answers — the ones that decide treatment — come only from a biopsy.
A biopsy removes a small sample of the suspicious area so a pathologist can examine it under the microscope. This is the only step that confirms cancer and starts to characterise it. The method is chosen for the situation — most women have a core needle biopsy, often guided by ultrasound for accuracy.
A hollow needle removes thin cores of tissue, enough to confirm cancer and run grade and receptor tests. It is the preferred breast biopsy — details on our core needle biopsy page.
A very thin needle draws out cells, useful for cysts and lymph nodes. It is quick but gives less information than a core — compare them on our FNAC page.
Ultrasound or stereotactic (mammogram) guidance ensures the needle reaches the exact spot, even for lumps that cannot be felt or that show only as microcalcifications.
Beyond "cancer or not", the report names the cancer type (such as invasive ductal carcinoma), its grade, and its ER, PR and HER2 status — the basis of your whole treatment plan.
Getting the diagnosis right — accurately and quickly — shapes everything that follows. CION brings imaging, biopsy, pathology and oncology together so your results are reviewed by a full team, with no unnecessary tests and no delay in starting the right treatment.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumour-board-reviewed diagnosis across 35+ centres in Telangana & AP. Call 1800-202-8726.
For most women the journey is faster and less frightening than expected. It moves from noticing a change, through assessment, to a confirmed answer — and only a minority of breast changes turn out to be cancer. Knowing the sequence helps you understand each appointment and ask the right questions.
At CION the steps are coordinated so you are not left waiting between tests, and a specialist explains every result in plain language.
Once cancer is confirmed, the next question is how far it has spread — its stage. Staging combines the tumour's size, whether the underarm lymph nodes are involved, and whether there is any spread to distant organs. It does not change what the cancer is, but it strongly shapes the treatment plan and outlook.
Not every woman needs every scan; the tumour board orders staging tests appropriate to the situation, avoiding unnecessary radiation and cost.
The most important part of the diagnosis for choosing treatment is not the size — it is the cancer's biology. Two tests on the biopsy tissue decide which drugs will work: the grade (how abnormal the cells look and how fast they divide) and the receptor status measured by immunohistochemistry (IHC).
These are the same tests that define the breast cancer subtypes — hormone-receptor-positive, HER2-positive and triple-negative — each of which is treated quite differently.
This page is the hub for breast cancer diagnosis. Whatever stage of the journey you are at — booking your first scan, waiting for biopsy results, or trying to understand a finished report — there is a detailed page for each step. Use the links below to go deeper into any test that matters to you.
Compare the three breast imaging tests: the mammogram, breast ultrasound and breast MRI — what each shows and when it is used.
Understand the breast biopsy overall, and the two main techniques: the core needle biopsy and FNAC.
Make sense of your pathology report with our guides to breast cancer grade and IHC and tumour markers (ER, PR, HER2, Ki-67).
Waiting for answers is the hardest part. CION offers a clear, woman-led pathway that takes you from your first worry to a confident, complete diagnosis — coordinated, affordable, and with your first consultation free.
A specialist listens to your story, examines you, reviews any scans or reports you already have, and explains which tests you actually need — no rushed decisions, no unnecessary tests.
Mammogram, ultrasound or MRI as needed, followed by an image-guided biopsy if anything is suspicious — arranged together, with up to 50% discounts on diagnostics.
If cancer is confirmed, we complete the receptor testing, grading and staging that fully characterise it — so nothing important is missed before treatment is planned.
3+ oncologists review your full diagnosis together and design your treatment, explained to you in plain language with transparent costs throughout.
Hear from patients diagnosed and treated at CION — from first scan to recovery.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Breast cancer is diagnosed through a structured process called the triple assessment: a clinical breast examination, imaging (a mammogram and/or ultrasound, sometimes an MRI), and a biopsy. The clinical exam and imaging raise or lower suspicion, but the diagnosis is only confirmed when a pathologist examines biopsy tissue under the microscope. The same biopsy then reveals the cancer type, its grade, and its ER, PR and HER2 receptor status. If cancer is confirmed, a staging workup checks how far it has spread. Putting all of this together is what allows the team to plan the right treatment.
No. A mammogram, ultrasound or MRI can make cancer look very likely or very unlikely, and they are essential for finding and locating a problem — but no scan can prove cancer on its own. The diagnosis is always confirmed by a biopsy, where cells or tissue are examined under the microscope. This is important in both directions: a worrying scan still needs tissue confirmation before any treatment, and an apparently normal scan does not always rule cancer out if there is a clear lump or symptom. At CION we never start cancer treatment without a confirmed biopsy result.
The triple assessment is the internationally recommended way to evaluate any breast lump or change. It combines three things: a clinical examination by a doctor, imaging (mammogram and/or ultrasound, with MRI in selected cases), and a needle biopsy. The accuracy of all three together is much higher than any single test, which is why it is the standard everywhere. When the three agree, the result is very reliable; when they disagree, the team investigates further rather than guessing. It protects against both false reassurance (missing a cancer) and false alarms (over-treating a benign lump).
It varies, but the process is usually faster than people fear. The clinical exam and imaging can often be done on the same day, and a needle biopsy is a short outpatient procedure. The main wait is for the pathology result, which typically takes a few working days, with receptor testing sometimes adding a little more. At CION the steps are coordinated so you are not left waiting between tests, and a specialist explains each result as it comes. Remember that most breast changes investigated this way turn out not to be cancer.
A breast biopsy report does far more than say "cancer or not". If cancer is present, it names the type (for example invasive ductal carcinoma or invasive lobular carcinoma), the grade (how abnormal and fast-growing the cells are), and the receptor status — whether the cancer has estrogen receptors (ER), progesterone receptors (PR) and the HER2 protein. It may also report Ki-67, a marker of how fast the cells divide. Together these decide which treatments will work: hormone therapy, HER2-targeted therapy, chemotherapy, or a combination. This is why the report is the single most important document in planning your care.
Diagnosis confirms that cancer is present and what type it is; staging then measures how far it has spread. Staging uses the TNM system — the size of the tumour (T), whether the underarm lymph nodes are involved (N), and whether there is spread to distant organs (M). Not everyone needs every scan: most early cancers do not require bone scans or PET-CT, which are reserved for larger or node-positive disease. Modern staging also blends in the grade and receptor status, so biology and spread are considered together. The stage helps guide treatment and gives a realistic idea of the outlook.
It depends on your age, breast density and situation. A mammogram is the main test for women over 40 and is excellent at finding small cancers and microcalcifications. An ultrasound is added for younger women, dense breasts and during pregnancy, and to tell a solid lump from a cyst. An MRI is reserved for high-risk women, unclear findings, or mapping disease before surgery. Many women have just one or two of these, not all three. The aim is the right test for your breast, not the most tests — which is part of why we avoid unnecessary scans at CION.
Yes. CION offers a free first consultation for all cancer patients, including women who have found a lump, been recalled from screening, or already have scans or a biopsy report they want explained. It is a full 45-minute consultation — a specialist examines you, reviews any reports, and tells you exactly which tests you need, with up to 50% discounts on diagnostics. The whole pathway is coordinated so you are not sent back and forth, and your diagnosis is reviewed by a tumour board. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.